NFAT Inhibitor-1(Synonyms: VIVIT peptide)

NFAT Inhibitor-1;(Synonyms: VIVIT peptide) 纯度: 98.89%

NFAT Inhibitor (VIVIT peptide) 是一种 NFAT 的细胞渗透性肽抑制剂,可选择性抑制钙调磷酸酶介导的 NFAT 脱磷酸作用。

NFAT Inhibitor-1amp;;(Synonyms: VIVIT peptide)

NFAT Inhibitor-1 Chemical Structure

CAS No. : 249537-73-3

规格 价格 是否有货 数量
1 mg ¥700 In-stock
5 mg ¥2800 In-stock
10 mg ¥5100 In-stock
25 mg ¥9900 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

NFAT Inhibitor-1 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

NFAT Inhibitor (VIVIT peptide) is a cell-permeable peptide inhibitor of nuclear factor of activated Tcells (NFAT) that selectively inhibits calcineurin-mediated dephosphorylation of NFAT[1][2].

IC50 Target

Nuclear factor of activated Tcells (NFAT)[1][2]

体外研究
(In Vitro)

NFAT Inhibitor treatment significantly inhibits nuclear translocation of NFATc1 for 24 hours. Long-term treatment with VIVIT significantly inhibits the cytoplasmic levels of cathepsin K, TRAP, and MMP-9[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[2]

Cell Line: Human peripheral blood CD14+ monocytes
Concentration: 10 μM
Incubation Time: 24 hours or 21 days
Result: Short-term treatment with 10 μM, significantly inhibited nuclear translocation of NFATc1. Long-term treatment, significantly inhibited the cytoplasmic levels of cathepsin K, TRAP, and MMP-9.

分子量

1685.94

Formula

C75H120N20O22S

CAS 号

249537-73-3

Sequence

Met-Ala-Gly-Pro-His-Pro-Val-Ile-Val-Ile-Thr-Gly-Pro-His-Glu-Glu

Sequence Shortening

MAGPHPVIVITGPHEE

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

H2O : 100 mg/mL (59.31 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.5931 mL 2.9657 mL 5.9314 mL
5 mM 0.1186 mL 0.5931 mL 1.1863 mL
10 mM 0.0593 mL 0.2966 mL 0.5931 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Aramburu J, et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 1999 Sep 24;285(5436):2129-33.

    [2]. Ma JD, et al. Activation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis. Arthritis Rheumatol. 2019 Aug;71(8):1252-1264.

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)(Synonyms: LSKL, 血小板反应蛋白抑制剂 (TSP-1) 三氟醋酸盐)

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA);(Synonyms: LSKL, 血小板反应蛋白抑制剂 (TSP-1) 三氟醋酸盐) 纯度: 99.30%

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 是一种衍生自 LAP-TGFβ 的四肽,是一种竞争性的 TGF-β1 拮抗剂。LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 抑制 TSP-1 与 LAP 的结合并减轻肾间质纤维化和肝纤维化。LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 通过抑制 TSP-1 介导的 TGF-β1 活性来抑制蛛网膜下纤维化,防止慢性脑积水的发生并改善蛛网膜下腔出血后的长期神经认知缺陷。LSKL, Inhibitor of Thrombospondin (TSP-1) TFA 可以轻松穿越血脑屏障。

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)amp;;(Synonyms: LSKL, 血小板反应蛋白抑制剂 (TSP-1) 三氟醋酸盐)

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) Chemical Structure

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ¥1134 In-stock
5 mg ¥900 In-stock
10 mg ¥1300 In-stock
25 mg ¥2600 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • TGF-beta/Smad Compound Library
  • Anti-Cancer Compound Library
  • CNS-Penetrant Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Targeted Diversity Library
  • Anti-Colorectal Cancer Compound Library
  • Peptide Library

生物活性

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier[1][2].

IC50 Target

TGF-β1[1]

体外研究
(In Vitro)

The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling[1].
LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)[1]
Dosage: 1 mg/kg
Administration: Intraperitoneal injection
Result: Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus.

分子量

572.62

Formula

C23H43F3N6O7

Sequence

Leu-Ser-Lys-Leu

Sequence Shortening

LSKL

中文名称

LSKL, 血小板反应蛋白抑制剂 (TSP-1) 三氟醋酸盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 250 mg/mL (436.59 mM; Need ultrasonic)

H2O : 100 mg/mL (174.64 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7464 mL 8.7318 mL 17.4636 mL
5 mM 0.3493 mL 1.7464 mL 3.4927 mL
10 mM 0.1746 mL 0.8732 mL 1.7464 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.08 mg/mL (3.63 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.63 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.63 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.63 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31.

    [2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61.

    [3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.

Fibrinogen Binding Inhibitor Peptide

Fibrinogen Binding Inhibitor Peptide; 纯度: 98.41%

Fibrinogen Binding Inhibitor Peptide 是一种十二肽 (HHLGGAKQAGDV,H12),是纤维蛋白原 γ 链羧基末端序列 (γ400-411)。是活化糖蛋白 (GP) IIb/IIIa 配体的特异性结合位点。

Fibrinogen Binding Inhibitor Peptideamp;;

Fibrinogen Binding Inhibitor Peptide Chemical Structure

CAS No. : 89105-94-2

规格 价格 是否有货 数量
1 mg ¥800 In-stock
5 mg ¥1900 In-stock
10 mg ¥3200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Fibrinogen Binding Inhibitor Peptide 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cardiovascular Disease Compound Library
  • Peptide Library

生物活性

Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.

体外研究
(In Vitro)

Glycoprotein (GP) IIb/IIIa, which exists on the membrane of platelets, changes its form from inactive to active when platelets adhere to collagen exposed on sites of vascular injury. In the circulation, platelet aggregation is mediated by fibrinogen by bridging adjacent platelets through GPIIb/IIIa in an activation-dependent manner. A dodecapeptide HHLGGAKQAGDV (H12), corresponding to the fibrinogen γ-chain carboxy-terminal sequence (γ400-411), is a specific binding site of the ligand for activated GPIIb/IIIa[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1189.28

Formula

C50H80N18O16

CAS 号

89105-94-2

Sequence

His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val

Sequence Shortening

HHLGGAKQAGDV

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Okamura Y, et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membraneproperties and their hemostatic effects as a platelet substitute. J Control Release. 2010 Dec 20;148(3):373-9.

Rac1 Inhibitor W56 TFA

Rac1 Inhibitor W56 TFA; 纯度: 98.53%

Rac1 Inhibitor W56 TFA 是 Rac1 中的残基 45-60。Rac1 Inhibitor W56 TFA 抑制 Rac1 与鸟嘌呤核苷酸交换因子 TrioN、GEF-H1 和 Tiam 的相互作用。

Rac1 Inhibitor W56 TFAamp;;

Rac1 Inhibitor W56 TFA Chemical Structure

规格 价格 是否有货 数量
1 mg ¥2200 In-stock
5 mg ¥7700 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Rac1 Inhibitor W56 TFA is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 TFA inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam[1].

分子量

1785.95

Formula

C76H118F3N19O25S

Sequence

Met-Val-Asp-Gly-Lys-Pro-Val-Asn-Leu-Gly-Leu-Trp-Asp-Thr-Ala-Gly

Sequence Shortening

MVDGKPVNLGLWDTAG

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 100 mg/mL (55.99 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.5599 mL 2.7996 mL 5.5993 mL
5 mM 0.1120 mL 0.5599 mL 1.1199 mL
10 mM 0.0560 mL 0.2800 mL 0.5599 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Gao Y, Xing J, et al. Trp(56) of rac1 specifies interaction with a subset of guanine nucleotide exchange factors [published correction appears in J Biol Chem. 2005 Jan 14;280(2):1704]. J Biol Chem. 2001;276(50):47530-47541.

PKG inhibitor peptide

PKG inhibitor peptide; 纯度: 98.15%

PKG inhibitor peptide 是一种 ATP 竞争性的 PKG 抑制剂,Ki 值为 86 μM。

PKG inhibitor peptideamp;;

PKG inhibitor peptide Chemical Structure

CAS No. : 82801-73-8

规格 价格 是否有货 数量
1 mg ¥900 In-stock
5 mg ¥2800 In-stock
10 mg ¥4500 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

PKG inhibitor peptide 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Peptide Library

生物活性

PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM[1].

IC50 Target

Ki: 86 μM (PKG)[1]

体外研究
(In Vitro)

Summary of experiments showing that intracellular dialysis of postsynaptic cells with PKG inhibitor PKG inhibitor peptide (1 mM) failed to alter the induction of long-term depression (CCh-LTD)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

943.11

Formula

C38H74N18O10

CAS 号

82801-73-8

Sequence Shortening

RKRARKE

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

H2O : 100 mg/mL (106.03 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0603 mL 5.3016 mL 10.6032 mL
5 mM 0.2121 mL 1.0603 mL 2.1206 mL
10 mM 0.1060 mL 0.5302 mL 1.0603 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Bhatnagar D, et al. Synthetic peptide analogues differentially alter the binding affinities of cyclic nucleotide dependent protein kinases for nucleotide substrates. Biochemistry. 1988 Mar 22;27(6):1988-94.

    [2]. Chiung-Chun Huang, et al. Activation of muscarinic acetylcholine receptors induces a nitric oxide-dependent long-term depression in rat medial prefrontal cortex. Cereb Cortex. 2010 Apr;20(4):982-96.

187-1, N-WASP inhibitor TFA

187-1, N-WASP inhibitor TFA;

187-1, N-WASP inhibitor TFA 是一种14-aa 环肽,也是一种变构神经 Wiskott Aldrich 综合征蛋白 (N-WASP) 抑制剂。187-1, N-WASP inhibitor TFA 有效抑制由磷脂酰肌醇 4,5-二磷酸酯 (PIP2) 诱导的肌动蛋白装配,IC50 为 2 μM。187-1, N-WASP inhibitor TFA 通过稳定蛋白质的自抑制状态,阻止了 N-WASP 激活 Arp2/3

187-1, N-WASP inhibitor TFAamp;;

187-1, N-WASP inhibitor TFA Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor TFA potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor TFA prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein[1][2].

分子量

1898.13

Formula

C98H123F3N18O18

Sequence

Cyclo[Gln-Lys-{d-Phe}-{d-Pro}-{d-Phe}-Phe-{d-Pro}-Gln-Lys-{d-Phe}-{d-Pro}-{d-Phe}-Phe-{d-Pro}]

Sequence Shortening

Cyclo[QK-{d-Phe}-{d-Pro}-{d-Phe}-F-{d-Pro}-QK-{d-Phe}-{d-Pro}-{d-Phe}-F-{d-Pro}]

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Peterson, et al. A chemical inhibitor of N-WASP reveals a new mechanism for targeting protein interactions. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10624-9.

    [2]. S Suetsugu, et al. Identification of another actin-related protein (Arp) 2/3 complex binding site in neural Wiskott-Aldrich syndrome protein (N-WASP) that complements actin polymerization induced by the Arp2/3 complex activating (VCA) domain of N-WASP. J Biol Chem. 2001 Aug 31;276(35):33175-80.

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II;

Human PD-L1 inhibitor II 是有效 PD-L1 抑制剂,具有抗癌活性。

Human PD-L1 inhibitor IIamp;;

Human PD-L1 inhibitor II Chemical Structure

CAS No. : 2135542-85-5

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity[1].

分子量

2219.45

Formula

C103H151N25O30

CAS 号

2135542-85-5

Sequence

Phe-Asn-Trp-Asp-Tyr-Ser-Leu-Glu-Glu-Leu-Arg-Glu-Lys-Ala-Lys-Tyr-Lys

Sequence Shortening

FNWDYSLEELREKAKYK

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Honglin Li, et al. Pd-1 targeting polypeptide and use thereof. WO2017162208A1

Lyn peptide inhibitor TFA

Lyn peptide inhibitor TFA;

Lyn peptide inhibitor TFA 是一种有效的,可以细胞渗透的抑制剂,抑制 Lyn 偶联的 IL-5 受体相关信号通路,同时保持其他信号的完整。Lyn peptide inhibitor TFA 可以阻断 Lyn 的激活,抑制 Lyn 酪氨酸激酶与 IL-3/GM-CSF/IL-5 受体的 βc 亚基结合。Lyn peptide inhibitor TFA可用于哮喘、过敏等嗜酸性疾病的研究。

Lyn peptide inhibitor TFAamp;;

Lyn peptide inhibitor TFA Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of  asthma, allergic, and other eosinophilic disorders[1].

IC50 Target[1][2]

IL-5

;

IL-3

;

分子量

2484.90

Formula

C116H186F3N30O26

Sequence

Stearoyl-Tyr-Gly-Tyr-Arg-Leu-Arg-Arg-Lys-Trp-Glu-Glu-Lys-Ile-Pro-Asn-Pro-NH2

Sequence Shortening

Stearoyl-YGYRLRRKWEEKIPNP-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. T Adachi, et al. The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor. J Immunol. 1999 Feb 1;162(3):1496-501.

    [2]. T Adachi, et al. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J Immunol. 1999 Jul 15;163(2):939-46.

PDZ1 Domain inhibitor peptide TFA

PDZ1 Domain inhibitor peptide TFA;

PDZ1 Domain inhibitor peptide TFA 是一种环状肽,结合 β-Ala 内酰胺侧链接头,并靶向 PSD-95 的 PDZ1 域。PDZ1 Domain inhibitor peptide TFA 破坏 GluR6/PSD-95 的相互作用,可以与 GluR6 的 C 末端竞争在 PDZ1 域的结合。

PDZ1 Domain inhibitor peptide TFAamp;;

PDZ1 Domain inhibitor peptide TFA Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain[1].

分子量

933.97

Formula

C40H62F3N9O13

Sequence Shortening

YKKTEAV (Lactam bridge:Lys3-Glu5)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Andrea Piserchio, et al. Targeting specific PDZ domains of PSD-95; structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem Biol. 2004 Apr;11(4):469-73.

Rac1 Inhibitor W56

Rac1 Inhibitor W56;

Rac1 Inhibitor W56 是 Rac1 中的残基 45-60。Rac1 Inhibitor W56 抑制 Rac1 与鸟嘌呤核苷酸交换因子 TrioN、GEF-H1 和 Tiam 的相互作用。

Rac1 Inhibitor W56amp;;

Rac1 Inhibitor W56 Chemical Structure

CAS No. : 1095179-01-3

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Rac1 Inhibitor W56 的其他形式现货产品:

Rac1 Inhibitor W56 TFA

生物活性

Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam[1].

分子量

1671.93

Formula

C74H117N19O23S

CAS 号

1095179-01-3

Sequence

Met-Val-Asp-Gly-Lys-Pro-Val-Asn-Leu-Gly-Leu-Trp-Asp-Thr-Ala-Gly

Sequence Shortening

MVDGKPVNLGLWDTAG

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Gao Y, Xing J, et al. Trp(56) of rac1 specifies interaction with a subset of guanine nucleotide exchange factors [published correction appears in J Biol Chem. 2005 Jan 14;280(2):1704]. J Biol Chem. 2001;276(50):47530-47541.